Medsintez Plant was recognized as a winner of the Sverdlovsk Region's Production Standards and Occupational Safety Competition for 2025, taking second place in the Chemical and Petrochemical Industry category. A total of 65 regional companies participated in the competition organized by the Department of Labor and Employment of the Sverdlovsk Region.
Medsintez Plant, one of Russia's largest vertically integrated pharmaceutical companies, has supported the launch of a new educational track at the Novouralsk College of Technology under the federal professional education programme—Professionalitet. The initiative is the result of a socially significant cooperation between the Medsintez plant, local educational institutions, and the Government of the Sverdlovsk Region. The company will invest 8 million rubles in the project.
On September 11–17, 2026, Ekaterinburg hosted the International Youth Festival, a large-scale event that brought together 10,000 young leaders from 191 countries. At the festival running under the motto «Follow Your Dream,» the Medsintez Plant presented its exhibition, showcasing the achievements of the Ural pharmaceutical industry in the field of import substitution.
The updated clinical guidelines for treatment of ARVI in children took effect on September 2, 2026. The document was developed by leading experts from the Union of Pediatricians of Russia, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and the Russian Society of Emergency Medical Care and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. It fundamentally shifts therapeutic approaches toward enhanced safety and minimal drug burden.

The company “Prostor Pharma” is a Russian pharmaceutical company that is part of the Farmatom Group of companies and specializes in the development and production of radiopharmaceutical medicines (RPHLP).
The company cooperates with leading manufacturers, suppliers of radiopharmaceutical products, equipment, engineering companies, medical and scientific institutions, conducts research activities and has expertise in all areas of nuclear medicine.
The issue of RPHLP of the Company “Prostor Pharma” is developing in two directions:
RPHLP production is carried out on a full cycle, in strict accordance with the requirements of the EAEU GMP good manufacturing practice.
The manufacture of RFLP is carried out in accordance with the mechanism of the «nuclear pharmacy» (pharmacy in GMP production).
In 2024, the company registered the world's first reproduced radium chloride radiopharmaceutical, 223Ra, for the treatment of patients with bone metastases in prostate cancer. Since 2024, The local drug has completely displaced its foreign counterpart and is now supplied to more than 40 medical institutions in Russia, in seven of the eight federal districts.
Prostor Pharma's production sites are located in Yekaterinburg, on the territory of the Ural Federal State University named after the First President of Russia B.N. Yeltsin, as well as in Ulan-Ude (Ulan-Ude Nuclear Medicine Center).
The site in Yekaterinburg is licensed by the Russian Ministry of Industry and Trade L012-00102-77/04180577) for the production of medicines for medical use and clinical research.
Website address: prostorpharma.ru
Phone number: 8 (800) 550-16-66
E-mail: info@prostorfarma.ru

Radium chloride, 223 Ra 177Lu-DOTA-TATE 177Lu-PSMA I&T